SS Innovations Submits Response to FDA Request for Additional Information Regarding the Company’s 510(k) Submission for the SSi MantraFORT LAUDERDALE, Fla., Oct. 13, 2026 (GLOBE NEWSWIRE) -- via IBN -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (
NASDAQ: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today announced that, on October 5, 2026, the Company submitted its response to a request for additional information letter (the “AINN”) received from the United States Food and Drug Administration (the “FDA”) with regard to the Company’s 510(k) submission for its SSi Mantra surgical robotic system (the “SSi Mantra”).
SS Innovations Provides Update on Continuing Progress and Milestones-- Advancing global expansion, pediatric robotic surgery and telesurgery --
SS Innovations Reports Second Quarter 2026 Financial ResultsRecord quarterly revenue driven by continuing strong growth in SSi Mantra unit sales
SS Innovations To Showcase the SSi Mantra Surgical Robotic System at SRS 2026Company’s advanced surgical robotic system will be on display, spotlighted in multiple breakout sessions, and featured in a kidney telesurgery to be broadcast live at the premier industry event
SS Innovations Appoints Sarah M. Romano as Chief Financial OfficerVeteran medtech finance executive brings extensive public company and capital markets experience to support the Company's next phase of global growth
SS Innovations Subsidiary SSICRS Graduates Inaugural Cardiac Robotic Surgery Training ClassNew course empowers healthcare professionals through expert instruction and hands-on learning
